The new anticoagulants: New opportunities, new issues

Archives of Pathology and Laboratory Medicine

Volumn 122, Issue 9, 1998, Pages 812-816

  Vlasuk, George P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ACUTE DISEASE; BLOOD; BLOOD CLOTTING; CHRONIC DISEASE; DRUG EFFECT; HUMAN; REVIEW; THROMBOSIS;

ACUTE DISEASE; ANTICOAGULANTS; BLOOD COAGULATION; CHRONIC DISEASE; HUMANS; THROMBOSIS;

EID: 0032160868     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rappaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;10:1111 -1121.
2. Hirsh J. Hepari'ns. Fibrinolysis. 1995;2:66-68.
3. Hirsh J, Fuster V. Guide to anticoagulant therapy, Part 2: oral anticoagulants. Circulation. 1994;89:1469-1480.
4. Gullov AL, Koefoed BG, Ptersen PJ. Bleeding complications to long-term oral anticoagulant therapy. Thromb Thrombolysis. 1994;1:17-25.
5. Hirsh J, Salzman EVV, Marder V), Colman RVV. Overview of the thrombotic process and its therapy. In: Colman RW, Hirsh J, Marder VJ, Salzman R, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa:JB Lippincott Co; 1994:1151-1163.
6. Eriksson Bl, Ekman S, Kalebo P, Zachrisson B, Bach D. Prevention of deepvein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347:635-G36.
7. Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation. Circulation. 1994;90:2147.
8. Loscalzo ). Thrombin inhibitors in fibrinolysis: a Hobson's choice of alternatives. Circulation. 1996;94:863-865.
9. Conrad KA. Clinical pharmacology and drug safety: lessons from hirudin. Clin Pharmacol Ther. 1996;58:123-126.
10. Kalafatis M, Mann KG. Factor VLeiden and thrombophilia. Arterioscler Thromb Vase Biol. 1997;! 7:620-627.
11. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest. 1983;71:1383-1391.
12. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vase Biol. 1996;16:1285-1291.
13. Vlasuk GP. Direct factor Xa inhibitors. In: Hirsh J, Loscalzo J, Sasahara A, VVeilz ), eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker Inc; 1997:261-283.
14. Lawson JH, Kalifatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin: an empirical study. J Biol Chem. 1994;269:23357-23366.
15. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol. 199l;29:213-226.
16. Girard T). Tissue factor pathway inhibitor. In: Hirsh ), Loscalzo J, Sasahara A, Weitz ), eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker Inc; 1997:225-260.
17. Kirchofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors Vila and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vase Biol. 1995;15:1098-1106.
18. Jang Y, Guzman LA, Lincoff AM, et al. Influcence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92:3041-3050.
19. Stanssens P, Bergum PVV, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. ProcNatlAcadSei USA. 1996;93:21492154.
20. Vlasuk GP, Bergum PW, Bradbury AE, Loynds P, Man! TGK, Rote WE. Clinical evaluation of rNAPc2, an inhibitor of the (Vila/tissue factor coagulation complex. AmJCardiol. 1997;80(70A):665. Abstract TCT-239.
21. Erickson BR, Topol EJ. Direct thrombin inhibitors in arterial thrombosis. In: Hirsh |, Loscalzo J, Sasahara A, Weitz J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: Marcel Dekker Inc; 1997:169-189.
22. Granger CB, Hirsh ), Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation. 1996;93:870-878.
23. Mannucci PM. Mechanisms, markers and management of coagulation activation. Brit Med Bull. 1994;50:851-870.
24. Owens J. The utility of plasma fibrinopeptide assays. Thromb Haemostat. 1989;62:807-810.
25. Miller G), Bauer KA, Barzegar S, et al. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995;73:82-86.
26. Philippou H, Adami A, Boisclair MD, Lane D. An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. Brit] Haemost. 1995;90:432-437.
27. Ripka WC, Vlasuk GP. Antithrombotics/serine proteases. Ann Rep Med Chem. 1997;32:71-89.
28. Johnson PH, Sze P, VVinant R, Payne PW, Lazar JB. Biochemistry and genetic engineering of hirudin. Semin Thromb Hemost. 1989;15:302-315.
29. Dodt J, Seemüller U, Maschler R, Fritz H. The complete covalent structure of hirudin: localization of the disulfide bonds. Bio Chem Hoppe Seyler. 1985; 366:379-385.
30. Dodt J, Müller HP, Seemüller U, Chang J-Y. The complete amino acid sequence of hirudin, a thrombin-specific inhibitor. ffS Lett. 1984;!65:180-183.
31. Badgy D, Barabas E, Graf L. Large scale preparation of hirudin. Thromb Res. 1973;2:229-238.
32. Cannon CP, McCabe CH, Henry TD, Becker RC. A pilot trial of recombinant , desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. Mm Coll Cardiol. 1994;23:9931003. " "
33. Lee LV, McCabe CH, Amman EM, et al. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI 6 trial. Am I Card/oJ. 1995;75:7-13.
34. Amman E, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report for the thrombolysis and thrombin inhibition (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
35. Topol E), Fuster V, Harrington RA, el al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographie trial. Circulation. 1994; 89:1557-1566.
36. The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO) lia Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
37. Neuhaus K-L, v Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation. 1994;90:1638-1642.